Tiv­dak gets pri­ma­ry end­point in PhI­II con­fir­ma­to­ry study

Gen­mab and Seagen’s cer­vi­cal can­cer drug Tiv­dak has reached its pri­ma­ry end­point in a con­fir­ma­to­ry Phase III tri­al, and the re­sults are ex­pect­ed to sup­port their bid to pur­sue full ap­proval of the an­ti­body-drug con­ju­gate in cer­vi­cal can­cer.

The FDA in 2021 grant­ed Tiv­dak, al­so known as ti­so­tum­ab ve­dotin-tftv, an ac­cel­er­at­ed ap­proval as a sec­ond-line treat­ment for pa­tients with re­cur­rent or metasta­t­ic cer­vi­cal can­cer af­ter chemother­a­py or dis­ease pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER